T81.4
Conditions
Interventions
Group 1: Retrospective analysis of routine clinical data from 150 patients who underwent pancreatic surgery between January and March 2025 and received Ampicillin/Sulbactam as perioperative antibiotic
Sponsors
Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: planned pancreatic surgery
Exclusion criteria
Exclusion criteria: Known allergy to piperacillin/tazobactam or ampicillin/sulbactam, inability to administer antibiotics for medical reasons, pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of overall wound infection rates, including superficial wound infections, deep incisional wound infections, and organ/body cavity infections within the first 10 days (± 2 days) after the index surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Parameters assessed include the duration of postoperative intensive care unit stay, length of hospital stay, hospital readmissions, duration of antibiotic therapy, postoperative day of surgical site infection (SSI) diagnosis, course of infection parameters, reoperations, in-hospital mortality and morbidity (Comprehensive Complication Index), specific postoperative complications, intraoperative bile samples, bile leaks, anastomotic insufficiencies, postoperative pancreatic fistulas, lymphatic fistulas, postoperative bleeding, postoperative acute pancreatitis, necessity for percutaneous or transgastric drainages, functional outcomes, delayed gastric emptying, nosocomial infections (urinary tract infections, pneumonia, bacteremia), Clostridium difficile-associated diarrhea, myocardial infarctions, pulmonary embolisms, strokes, identified bacterial species in samples, and antibiotic resistances of isolated pathogens. | — |
Countries
Germany
Contacts
Public ContactJulian-Camill Harnoß
Universitätsklinikum Heidelberg Klinik für Allgemein-, Viszeral- und Transplantationschirurgie
Outcome results
None listed